KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)Dividends Paid - Common Growth (5y)Dividends payables Growth (1y)Dividends payables Growth (3y)Dividends payables Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)FCF Payout Ratio Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Others
Ratios

Pfizer (PFE) Net Cash Flow Growth (1y) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -568.73%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -85.99%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 1,265.92%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -95.55%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 191.97%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 103.60%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 42.41%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -227.06%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 42.41%
Sep 28, 2025 82.41%
Jun 29, 2025 -51.94%
Mar 30, 2025 118.11%
Sep 29, 2024 -405.84%
Jun 30, 2024 -25.16%
Mar 31, 2024 -220.10%
Oct 1, 2023 211.44%
Jul 2, 2023 177.21%
Apr 2, 2023 231.32%
Oct 2, 2022 -187.87%
Jul 3, 2022 -202.98%
Apr 3, 2022 3,412.50%
Oct 3, 2021 104.28%
Jul 4, 2021 -11.16%
Apr 4, 2021 86.21%
Sep 27, 2020 -1,419.06%
Jun 28, 2020 579.58%
Mar 29, 2020 -114.85%
Dec 31, 2019 83.87%
Sep 29, 2019 7.80%
Jun 30, 2019 -130.54%
Mar 31, 2019 -16.02%
Dec 31, 2018 -560.01%
Sep 30, 2018 468.26%
Jul 1, 2018 131.27%
Apr 1, 2018 -35.64%
Dec 31, 2017 -320.44%
Oct 1, 2017 112.79%
Jul 2, 2017 -275.77%
Apr 2, 2017 243.35%
Dec 31, 2016 -53.55%
Oct 2, 2016 -168.72%
Jul 3, 2016 662.16%
Apr 3, 2016 -442.86%
Dec 31, 2015 44.05%
Sep 27, 2015 49.32%
Jun 28, 2015 -79.44%
Mar 29, 2015 -58.24%
Dec 31, 2014 685.25%
Sep 28, 2014 -187.13%
Jun 29, 2014 -4.59%
Mar 30, 2014 108.60%
Dec 31, 2013 -97.80%
Sep 29, 2013 -122.80%
Jun 30, 2013 240.96%
Mar 31, 2013 -2,803.90%
Dec 31, 2012 1,342.06%
Sep 30, 2012 136.67%
Jul 1, 2012 -92.91%
Apr 1, 2012 72.81%
Dec 31, 2011 4.08%
Oct 2, 2011 121.07%
Jul 3, 2011 1,450.33%
Apr 3, 2011 -485.88%
Dec 31, 2010 79.53%
Oct 3, 2010 -85.82%
Jul 4, 2010 -84.09%
Apr 4, 2010 79.23%